Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fubishu is a traditional Chinese medicine (TCM) developed and manufactured by Zhejiang Kangde Pharmaceutical. It is formulated as an effervescent vaginal tablet specifically designed for the treatment of various gynecological inflammatory conditions. The medication is primarily indicated for vaginitis (including bacterial, trichomonal, and fungal/candidal types) and cervicitis, particularly when associated with symptoms such as abnormal vaginal discharge (leukorrhea), pruritus vulvae, and local redness or swelling. As a TCM formulation, it typically incorporates herbal extracts known for their antimicrobial, anti-inflammatory, and 'heat-clearing' properties. The effervescent dosage form allows for rapid disintegration and uniform distribution of the active ingredients within the vaginal cavity, providing localized therapeutic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fubishu.